KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Other Non-Current Liabilities (2016 - 2025)

Amgen has reported Other Non-Current Liabilities over the past 17 years, most recently at $2.4 billion for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $2.4 billion for Q4 2025, up 1.23% from a year ago — trailing twelve months through Dec 2025 was $2.4 billion (up 1.23% YoY), and the annual figure for FY2025 was $2.4 billion, up 1.23%.
  • Other Non-Current Liabilities for Q4 2025 was $2.4 billion at Amgen, down from $2.6 billion in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for AMGN hit a ceiling of $6.7 billion in Q1 2022 and a floor of $96.0 million in Q1 2024.
  • Median Other Non-Current Liabilities over the past 5 years was $2.3 billion (2023), compared with a mean of $2.4 billion.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 98.27% in 2023 and later soared 2419.79% in 2025.
  • Amgen's Other Non-Current Liabilities stood at $342.0 million in 2021, then fell by 21.05% to $270.0 million in 2022, then surged by 761.48% to $2.3 billion in 2023, then grew by 0.99% to $2.3 billion in 2024, then rose by 1.23% to $2.4 billion in 2025.
  • The last three reported values for Other Non-Current Liabilities were $2.4 billion (Q4 2025), $2.6 billion (Q3 2025), and $2.5 billion (Q2 2025) per Business Quant data.